ClinicalTrials.gg
Active, not recruitingNCT05575830Shingr'HIVUpdated Sep 5, 2025

Immune Response of Shingrix Vaccine in People Living With HIV (> 50 y.o.) Compared to Age-matched Controls

A Phase 4 interventional study of Recombinant Zoster Vaccine in RZV Vaccine (Shingrix ®), sponsored by Calmy Alexandra. Active, not recruiting at 10 sites in 2 countries. Open to participants aged 50 Years to 95 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-05.

Sponsored by Calmy Alexandra · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
225
Allocation
Not applicable
Ages
50 Years to 95 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the efficacy and safety of the adjuvanted recombinant Zoster vaccine (RZV, or Shingrix®) in older people (> 50 years) living with HIV (PLWH) compared to age-matched healthy adults over a 1-year period.

Read the detailed description

This is a prospective multicentric phase IV study, aiming at evaluating the immunogenicity and safety profile of RZV in PLWH over 50 years of age (YOA) on long term antiretroviral therapy (ART) (>10 years) compared to non-HIV age-matched adult controls to address the combined effect of aging and immunosuppression from HIV disease.

Inclusion will be stratified as follow:

HIV+ groups:

  • Group 1: PLWH registered in the SHCS or ANRS CO3, >75 YOA and under cART for more than 10 years - N=50
  • Group 2: PLWH patients registered in the SHCS, aged between 60 and 75 and under cART for more than 10 years - N=50
  • Group 3: PLWH patients registered in the SHCS, aged between 50 and 59 and under cART for more than 10 years - N=50

Control groups:

  • Group 4: Healthy adults aged >75 YOA- N=25
  • Group 5: Healthy adults aged between 60 and 75 - N=25
  • Group 6: Healthy adults aged between 50 and 59 - N=25

In addition, participants of all groups will be proposed to be included in the "Innate substudy" (target of 15 participants/group) and have two additional blood drawings 1 day after each vaccine dose to measure innate response triggered by RZV.

Participants will receive Shingrix® on Day0 and Day60; immunological response will be assessed on Day 1, Day61, Day90, Day360.

Unsolicited Adverse events of special intesrest (AESI) will be collected on Day 28, Day 60, Day90, Day360; patients reported outcomes (PROs) will be declared for one week after each vaccination.

02

Conditions studied

  • RZV Vaccine (Shingrix ®)

Keywords

  • RZV vaccine
  • PLWH
  • Immune response
  • Safety
03

In context

Lead sponsor

Calmy Alexandra is the lead sponsor of 7 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 95 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For PLWH:

  • Be registered in the SHCS or in the ANRS CO3 Aquitaine Cohort
  • Age >50 YOA
  • Time since cART initiation > 10 years
  • Not already vaccinated with RZV
  • viral load \<50 copies/ml (within 6 months from the last blood sampling)
  • as documented by signature
  • (France) : Person affiliated with or beneficiary of the French social security scheme

For aged/gender-matched controls

  • Age >50 YOA
  • Not already vaccinated with RZV
  • Informed consent as documented by signature
  • (France) Not HIV infected
  • (France) Person affiliated with or beneficiary of the French social security scheme

Exclusion criteria

Exclusion Criteria:

  • Ongoing signs of febrile or non-febrile infection at the time of the first vaccination
  • from the following:

    • Current malignant neoplasm;
    • primary immunodeficiency;
    • recent (\<2 years) solid or bone-marrow transplant or any transplant still requiring immunosuppressive therapy
  • Intake of drugs which suppress the immune system (e.g. for a long time [an equivalent dose of prednisolone >20 mg/day > 3 months], monoclonal antibodies, cytostatics, biological products, etc.) within 6 months before screening.
  • Administration of immunoglobulins or any blood products within 3 months preceding the first dose of vaccine or planned administration during the study period
  • Having received a vaccine in the last month or is expected to receive a vaccine in the next month
  • Having received a shingles vaccine within one year
  • Presented with herpes zoster in the previous year
  • to RZV
  • Hospitalized patients
  • Unable to provide or inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant
  • Participation in another study with drug within the 30 days preceding and during the present study.
  • (France) Pregnant or breastfeeding woman
  • (France) Patient governed by articles L 1121-5 to L 1121-8 (persons deprived of their liberty by a judicial or administrative decision, minors, persons of legal age who are the object of a legal protection measure or unable to express their consent)
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
225 participants (estimated)

Study arms

  • Experimental
    RZV or Shingrix®)

    Recombinant Zoster Vaccine

    Biological: Recombinant Zoster Vaccine

Interventions

  • BiologicalShingrixStudies of ShingrixShingrix pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Shingrix® vaccine will be administered in two vaccinations on Day0 and Day60

    Also known as: (Shingrix® )

06

What researchers measure

Primary outcomes

  1. Geometric mean titer (GMT) of gE-specific total IgG

    gE-specific total IgG titers is determined by gE-specific ELISA from sera samples

    Time frame: Day 90

Secondary outcomes

  1. Vaccine safety - AESI 7 days

    Incidence adverse events of special interest (AESI) in the 7 days following each vaccination (reactogenicity) collected in a diary card

    Time frame: 7 days

  2. Vaccine safety - SAE 360 days

    Incidence of SAE throughout the study period

    Time frame: 360 days

  3. Vaccine safety -pIMDs

    Incidence of potential immune mediated disorders (pIMDs) throughout the study period

    Time frame: 360 days

  4. Vaccine safety - PLWH

    In PLWH: Percentage of PLWH with viral load \>50 copies/ml one month after the second RZV vaccination (D90)

    Time frame: Day 90

  5. Vaccine immunogenicity - CD4+ T cells

    Mean of gE-specific CD4+ T cells expressing at least 2 activation markers (i.e. CD40L, IFN-gamma, IL-2 or TNF-alpha) per million of T cells, measured at D90

    Time frame: Day 90

07

Study locations

10 sites
08

References and documents

Publications

  • Hentzien M, Bonnet F, Bernasconi E, Biver E, Braun DL, Munting A, Leuzinger K, Leleux O, Musardo S, Prendki V, Schmid P, Staehelin C, Stoeckle M, Walti CS, Wittkop L, Appay V, Didierlaurent AM, Calmy A. Immune response to the recombinant herpes zoster vaccine in people living with HIV over 50 years of age compared to non-HIV age-/gender-matched controls (SHINGR'HIV): a multicenter, international, non-randomized clinical trial study protocol. BMC Infect Dis. 2024 Mar 19;24(1):329. doi: 10.1186/s12879-024-09192-5. PubMed 38504173 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2022 to primary completion in Apr 2025, 28 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2022
First posted
Oct 12, 2022
StartActual
Dec 14, 2022
Primary completionActual
Apr 16, 2025
CompletionEst.
Mar 31, 2026
Last update
Sep 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05575830
Lead sponsor
Calmy Alexandra
Responsible party
Calmy Alexandra (Prof, University Hospital, Geneva) — Sponsor-investigator
First posted
Oct 12, 2022
Start date
Dec 14, 2022
Primary completion
Apr 16, 2025
Completion
Mar 31, 2026 (estimated)
Last update
Sep 5, 2025

Study contacts

Alexandra Calmy, Prof. MD
study director · University Hospitals of Geneva, Infectious disease department,

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Shingrix

Start the discussion